{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:52:05Z","timestamp":1789750325611,"version":"4.0.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jgar.2023.04.017","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:50:45Z","timestamp":1684363845000},"page":"304-320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-0767","authenticated-orcid":false,"given":"Stephen","family":"Hawser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimmi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8254-9651","authenticated-orcid":false,"given":"Ian","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4647-7467","authenticated-orcid":false,"given":"Tony","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.04.017_bib0001","unstructured":"European Medicines Agency. Antimicrobial resistance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/antimicrobial-resistance#:~:text=Antimicrobial%20resistance-%20is%20when%20a,inhibit%20the%20growth%20of%20bacteria. [accessed 30 May 2023]."},{"key":"10.1016\/j.jgar.2023.04.017_bib0002","series-title":"Global action plan on antimicrobial resistance","year":"2015"},{"key":"10.1016\/j.jgar.2023.04.017_bib0003","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. https:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf. [accessed 30 May 2023]."},{"key":"10.1016\/j.jgar.2023.04.017_bib0004","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgar.2023.04.017_bib0005","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2023.04.017_bib0006","doi-asserted-by":"crossref","first-page":"a025387","DOI":"10.1101\/cshperspect.a025387","article-title":"Tetracycline antibiotics and resistance","volume":"6","author":"Grossman","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jgar.2023.04.017_bib0007","series-title":"XERAVATM (eravacycline) [package insert]","year":"2019"},{"key":"10.1016\/j.jgar.2023.04.017_bib0008","doi-asserted-by":"crossref","first-page":"ofaa071","DOI":"10.1093\/ofid\/ofaa071","article-title":"Early experience with eravacycline for complicated infections","volume":"7","author":"Alosaimy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.04.017_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40121-020-00351-0","article-title":"A real-world assessment of clinical outcomes and safety of eravacycline: a novel fluorocycline","volume":"9","author":"Van Hise","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2023.04.017_bib0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jgar.2021.02.009","article-title":"Efficacy and safety of eravacycline: a meta-analysis","volume":"24","author":"Eljaaly","year":"2021","journal-title":"J Golb Antimicrob Res"},{"key":"10.1016\/j.jgar.2023.04.017_bib0011","first-page":"19","article-title":"In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013\u20132017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.04.017_bib0012","first-page":"e01715","article-title":"In vitro activity of eravacycline against Gram-positive bacteria isolated in clinical laboratories worldwide from 2013\u20132017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.04.017_bib0013","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.jgar.2023.04.017_bib0014","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2023"},{"key":"10.1016\/j.jgar.2023.04.017_bib0015","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 13.0. 2023. http:\/\/www.eucast.org. [accessed 30 May 2023]."},{"key":"10.1016\/j.jgar.2023.04.017_bib0016","unstructured":"US Food and Drug Administration. Antibacterial susceptibility test interpretative criteria. https:\/\/www.fda.gov\/drugs\/development-resources\/eravacycline-injection-products. [accessed 30 May 2023]."},{"key":"10.1016\/j.jgar.2023.04.017_bib0017","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Guidance document on tigecycline dosing. 2018. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/General_documents\/Tigecycline_Guidance_document_20181223.pdf. [accessed 30 May 2023]."}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:08Z","timestamp":1761991268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":17,"alternative-id":["S2213716523000747"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.04.017","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}